KPP Advisory Services LLC Has $2.23 Million Stake in Johnson & Johnson (NYSE:JNJ)

KPP Advisory Services LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 17.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,457 shares of the company's stock after purchasing an additional 1,965 shares during the quarter. KPP Advisory Services LLC's holdings in Johnson & Johnson were worth $2,232,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. MRP Capital Investments LLC boosted its position in Johnson & Johnson by 4.1% during the fourth quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock worth $237,000 after acquiring an additional 65 shares during the last quarter. Syverson Strege & Co lifted its position in Johnson & Johnson by 4.9% in the fourth quarter. Syverson Strege & Co now owns 1,394 shares of the company's stock valued at $202,000 after acquiring an additional 65 shares during the last quarter. Denali Advisors LLC grew its stake in Johnson & Johnson by 1.3% during the 4th quarter. Denali Advisors LLC now owns 5,128 shares of the company's stock worth $742,000 after buying an additional 67 shares during the last quarter. Sage Mountain Advisors LLC increased its stake in Johnson & Johnson by 0.5% in the fourth quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company's stock valued at $2,106,000 after purchasing an additional 67 shares during the period. Finally, Sovereign Financial Group Inc. increased its holdings in shares of Johnson & Johnson by 1.8% in the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock valued at $651,000 after purchasing an additional 69 shares during the period. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

NYSE:JNJ traded up $0.43 during trading hours on Friday, reaching $152.44. 9,999,068 shares of the company's stock were exchanged, compared to its average volume of 8,018,827. The business's 50-day simple moving average is $153.75 and its two-hundred day simple moving average is $153.76. The company has a market capitalization of $366.78 billion, a P/E ratio of 16.96, a price-to-earnings-growth ratio of 2.31 and a beta of 0.42. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. Sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, May 27th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.41%. Johnson & Johnson's dividend payout ratio is 57.84%.

Analysts Set New Price Targets

Several research analysts have issued reports on JNJ shares. Bank of America cut their price objective on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research report on Thursday, April 10th. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Barclays reduced their price objective on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Finally, Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Eleven research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.